Voxtalisib

• Description :

  Voxtalisib (XL765) is a potent PI3K inhibitor, which has a similar activity toward class I PI3K (IC50s=39, 113, 9 and 43 nM for p110α, p110β, p110γ and p110δ, respectively), also inhibits DNA-PK (IC50=150 nM) and mTOR (IC50=157 nM) . Voxtalisib (XL765) inhibits mTORC1 and mTORC2 with IC50s of 160 and 910 nM, respectively.

• Product Name Alternative :

  XL765; SAR245409

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  MTOR; PI3K

• Type :

  Reference compound

• Related Pathways :

  PI3K/Akt/mTOR

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/SAR245409.html

• Purity :

  99.82

• Solubility :

  DMSO : 10 mg/mL (ultrasonic)

• Smiles :

  O=C1C(C2=NNC=C2)=CC3=C(C)N=C(N)N=C3N1CC

• Molecular Formula :

  C13H14N6O

• Molecular Weight :

  270.29

• Precautions :

  H302

• References & Citations :

  [1]Garcia-Echeverria C, et al. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008 Sep 18;27 (41) :5511-26.|[2]Yu P, et al. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol Cancer Ther. 2014 May;13 (5) :1078-91.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  MTOR; mTORC1; mTORC2; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ

• CAS Number :

  [934493-76-2]